These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8704279

  • 1. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
    Yang X, Pagé M.
    Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
    [Abstract] [Full Text] [Related]

  • 2. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L, Tong Y, Jin Y, Zhou S, Zhang Y, Yang X, Mao N.
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [Abstract] [Full Text] [Related]

  • 3. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD, Li M, Yuan Y, Mao N, Pan LY.
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [Abstract] [Full Text] [Related]

  • 4. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC.
    Cancer Res; 1993 Nov 01; 53(21):5225-32. PubMed ID: 8106143
    [Abstract] [Full Text] [Related]

  • 5. Development of multidrug resistance in a canine lymphoma cell line.
    Uozurmi K, Nakaichi M, Yamamoto Y, Une S, Taura Y.
    Res Vet Sci; 2005 Jun 01; 78(3):217-24. PubMed ID: 15766940
    [Abstract] [Full Text] [Related]

  • 6. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H.
    Cancer Chemother Pharmacol; 2002 Jun 01; 49(6):438-44. PubMed ID: 12107547
    [Abstract] [Full Text] [Related]

  • 7. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 01; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 8. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
    Leveille-Webster CR, Arias IA.
    Clin Cancer Res; 1996 Apr 01; 2(4):695-706. PubMed ID: 9816220
    [Abstract] [Full Text] [Related]

  • 9. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
    Choi CH, Kang G, Min YD.
    Planta Med; 2003 Mar 01; 69(3):235-40. PubMed ID: 12677527
    [Abstract] [Full Text] [Related]

  • 10. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T, Guan M, Jin HY, Lu Y.
    Gynecol Oncol; 2005 May 01; 97(2):501-7. PubMed ID: 15863151
    [Abstract] [Full Text] [Related]

  • 11. [Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer].
    Liang Z, Bian D.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb 01; 31(2):75-8. PubMed ID: 8758797
    [Abstract] [Full Text] [Related]

  • 12. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP.
    Clin Cancer Res; 1998 Feb 01; 4(2):389-98. PubMed ID: 9516927
    [Abstract] [Full Text] [Related]

  • 13. Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea.
    Sosinski J, Thakar JH, Germain GS, Dias P, Harwood FC, Kuttesch JF, Houghton PJ.
    Mol Pharmacol; 1994 May 01; 45(5):962-70. PubMed ID: 7910660
    [Abstract] [Full Text] [Related]

  • 14. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS.
    Cancer Res; 1996 Dec 01; 56(23):5435-42. PubMed ID: 8968098
    [Abstract] [Full Text] [Related]

  • 15. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
    Minderman H, Vanhoefer U, Toth K, Minderman MD, Rustum YM.
    Cancer; 1996 Dec 01; 78(11):2427-36. PubMed ID: 8941015
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
    Chen G, Teicher BA, Frei E.
    Anticancer Res; 1996 Dec 01; 16(6B):3499-505. PubMed ID: 9042212
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.